Edmond de Rothschild Investment Partners’ BioDiscovery 4, its fourth fund dedicated to life sciences, has made its second investment through the series B financing round of Complix, which it co-leads with GIMV.
Complix, formed in 2008, was founded in Hasselt, Belgium. Edmond de Rothschild Investment Partners led alongside GIMV the Series B round financing of EUR12m which will be invested in developing a first set of therapeutic Alphabodies to treat cancer and autoimmune indications and to further develop and validate the company’s unique Alphabody platform.
Complix is developing Alphabodies, a transformative biotherapeutic platform with the ability to modulate the intracellular protein-to-protein interactions (PPIs), which play a key role in the initiation and progression of many important diseases. These Alphabodies have the capacity to address a vast number of disease targets that are currently considered "undruggable" by the two main classes of therapeutic drugs, small chemical drugs and therapeutic proteins, and represent a major medical and commercial opportunity for Complix and its partners.
Gilles Nobecourt, partner at Edmond de Rothschild Investment Partners, who will join the board of directors at Complix, says: "We were attracted by Alphabodies’ unique ability to modulate intracellular protein-protein interactions which offers an unprecedented opportunity to create a new class of proprietary and truly differentiated products. We were impressed by the team at Complix, which has created this new scaffold and demonstrated in-vitro its potential to address intractable intra cellular targets. Based on this initial success we believe there is a strong basis for building a successful company."
Mark Vaeck, co-founder and chief executive of Complix, says: "We look forward to working with our new investors Edmond de Rothschild Investment Partners and GIMV to ensure the expeditious implementation of our ambitious plans and vision. We are confident that our Alphabody platform can deliver the next generation drugs that the pharmaceutical industry is eagerly looking for to drive its growth and tackle a broad range of diseases where treatment options are limited or non-existent."
